Magnesium research最新文献

{"title":"A Road Map to the State of the Art of Magnesium Research - Highlights from the XVII International Magnesium Symposium, Grottaferrata 5-6 September 2024.","authors":"Federica I Wolf, Valentina Trapani, Jeanette A Maier","doi":"10.1684/mrh.2024.0531","DOIUrl":"https://doi.org/10.1684/mrh.2024.0531","url":null,"abstract":"","PeriodicalId":18159,"journal":{"name":"Magnesium research","volume":"37 3","pages":"1-6"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143023684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective effect of nano magnesium oxide on renal ischemia/reperfusion injury in male Wistar rats.","authors":"Marzieh Minaei, Akram Eidi, Pejman Mortazavi, Ahmad Asghari","doi":"10.1684/mrh.2024.0539","DOIUrl":"https://doi.org/10.1684/mrh.2024.0539","url":null,"abstract":"<p><p>Ischemia/reperfusion (I/R) injury is a main issue in renal transplantation, and antioxidants attenuate I/R injury in different tissues. We investigated the protective effects of nano magnesium oxide (nano-MgO) on renal I/R injury in rats. Induction of I/R injury was performed through clamping the left renal pedicle for 20 minutes. Animals were administrated with nano-MgO (1.25, 2.5 and 5 mg/kg) for 30 days by gavage, and were sacrificed for biochemical and histopathological studies. Our findings show that nano-MgO administration (2.5 and 5 mg/kg) in rats with renal I/R injury significantly attenuated serum creatinine and urea levels (p<0.001), decreased malondialdehyde (MDA) levels and elevated antioxidant enzyme activities in renal homogenates (p<0.001), as evidenced by histopathological assessment, and caused a significant reduction in EGF immunoreactivity and EGFR expression in renal tissues (p<0.001). In conclusion, nano-MgO administration preserves renal function and prevents tissue damage after I/R injury in rats.</p>","PeriodicalId":18159,"journal":{"name":"Magnesium research","volume":"37 4","pages":"189-202"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144016032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection and warning of drug-induced hypomagnesemia: a pharmacovigilance study of the FDA Adverse Event Reporting System.","authors":"Yanghai Xiao, Jianjiang Fang, Yixia Zhou, Ting Zhou","doi":"10.1684/mrh.2025.0546","DOIUrl":"https://doi.org/10.1684/mrh.2025.0546","url":null,"abstract":"<p><p>Hypomagnesemia, a common condition, frequently goes unnoticed due to varying symptom severity. In the hospital setting, the link between adverse drug reactions and hypomagnesemia is not always clear, and some drug labels omit this risk, compounding the potential danger. We conducted a cross-sectional study by mining data from the FDA Adverse Event Reporting System (FAERS) covering Q1 2004 to Q4 2023. Using the Medical Dictionary for Regulatory Activities, we identified cases of hypomagnesemia, determined the signal drugs causing hypomagnesemia based on the drug name, and employed descriptive and disproportionality analysis methods for signal detection. From 17,381,220 adverse event reports, 11,228 individual safety reports (ISRs) involving hypomagnesemia were identified. Omeprazole led with 1,556 reports (20.75%), followed by pantoprazole, panitumumab, cetuximab, and esomeprazole. Disproportionality analysis revealed necitumumab as the drug with the strongest signal, followed by capreomycin, panitumumab, pantoprazole, and omeprazole. Among the top 50 drugs from the disproportionality analysis, 31 signal drugs had labels that did not mention the risk of hypomagnesemia. We issue warnings regarding drugs associated with specific combination therapies that cause adverse reactions leading to hypomagnesemia. Furthermore, to delve deeper into the relationship between drugs and hypomagnesemia, reliance on more credible research in this field is required.</p>","PeriodicalId":18159,"journal":{"name":"Magnesium research","volume":"38 2","pages":"56-69"},"PeriodicalIF":1.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum magnesium concentration: time for a standardised and evidence-based reference range.","authors":"Heike Weisser, Klaus Kisters, Jürgen Vormann, Bodo von Ehrlich, Oliver Micke","doi":"10.1684/mrh.2025.0548","DOIUrl":"https://doi.org/10.1684/mrh.2025.0548","url":null,"abstract":"<p><p>Total serum magnesium concentration is rarely determined in clinical practice. Moreover, there is currently no standardised and evidence-based reference range for serum magnesium. The aim of this communication is to propose a reference range that is evidence-based and reflects the preventive potential of optimal magnesium levels. A literature search was conducted in the PubMed database using the terms \"serum magnesium\", \"reference interval\", \"reference range\", and \"hypomagnesemia\". Additionally, citations from relevant studies were consulted. There is considerable variation between laboratories with regards to the lower limit of magnesium in serum. The majority of limits are considerably below the 0.85 mmol/L (2.07 mg/dL) threshold proposed by expert groups. The rationale for this limit is that lower levels are associated with an increased risk of diseases such as type 2 diabetes and cardiovascular diseases. To prevent health risks associated with low magnesium levels, the lower limit of serum magnesium should be raised to 0.85 mmol/L and standardised between laboratories. At least, laboratory reports should note that levels below 0.85 mmol/L are associated with an increased risk of disease. Furthermore, the determination of serum magnesium should be afforded the same importance in routine laboratory diagnostics as the determination of other electrolytes.</p>","PeriodicalId":18159,"journal":{"name":"Magnesium research","volume":"38 2","pages":"41-44"},"PeriodicalIF":1.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Magnesium status, serum vitamin D concentration and mortality among congestive heart failure patients: a cohort study from NHANES 2007-2018.","authors":"Ling Sun, Jingyuan Du","doi":"10.1684/mrh.2024.0528","DOIUrl":"https://doi.org/10.1684/mrh.2024.0528","url":null,"abstract":"<p><p>This study aimed to evaluate the relationship between magnesium (Mg) status, serum vitamin D (VD) concentration and mortality in congestive heart failure (CHF) patients. Data for this study were extracted from the National Health and Nutrition Examination Surveys 2007-2018. Magnesium depletion score (MDS) is a scoring system developed to predict the status of Mg deficiency that considers the pathophysiological factors influencing the reabsorption capability of the kidneys. The primary outcome was all-cause mortality of CHF patients and the secondary outcome was mortality due to cardiovascular disease (CVD). Weighted univariate and multivariate cox proportional hazards models were used to explore the association between Mg status, serum VD concentration and all-cause mortality or mortality due to CVD in CHF patients, using hazard ratios (HRs) and 95 % confidence intervals (CIs). Subgroup analyses based on age, physical activity (PA), course of CHF, race, and body mass index were further assessed with regards to the association analysis. In total, 1022 CHF patients were included, of whom 418 (40.90 %) died by 31st December 2019. After adjusting for all covariates, high MDS (>2 points) was related to a higher risk of all-cause mortality (HR = 1.72, 95 % CI: 1.30-2.29) and mortality due to CVD (HR = 1.71, 95 % CI: 1.29-2.25); a higher serum VD concentration was related to a lower risk of all-cause mortality (HR = 0.78, 95 %CI: 0.62-0.99) and mortality due to CVD (HR = 0.80, 95 % CI: 0.63-0.99). Compared to patients with high serum VD concentration and low MDS, patients with low serum VD concentration and high MDS had a high risk of all-cause mortality (HR = 2.44, 95 % CI: 1.54-3.85, p for trend = 0.043) and mortality due to CVD (HR = 2.41, 95 % CI: 1.32-4.40). Serum VD and Mg status may have a combined effect in improving the prognosis in CHF patients, thus an appropriate level of serum VD and Mg intake may be beneficial to maintain cardiovascular health, thereby improving outcome.</p>","PeriodicalId":18159,"journal":{"name":"Magnesium research","volume":"37 2","pages":"61-75"},"PeriodicalIF":1.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142729872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urinary magnesium deficiency and acute urinary retention.","authors":"Jose Ponce Díaz-Reixa, Paula Fernández Suárez, Fernando Toba Alonso, Paula Gómez Fernández, Ana Díaz Pedrouzo, Eduardo Martins Santos, Elisa Fernández Rodriguez, Lucia García Arco, Marcos Aller Rodríguez, Sara Martínez Breijo, Iria Rodríguez Valladares, Leticia Quintana Rio, Venancio Chantada Abal","doi":"10.1684/mrh.2024.0529","DOIUrl":"https://doi.org/10.1684/mrh.2024.0529","url":null,"abstract":"<p><p>This prospective case-control study explored the association between urinary magnesium levels and acute urinary retention (AUR) in individuals presenting to the emergency department. Forty-six participants, comprising 23 cases and 23 age- and sex-matched controls, underwent urine analysis for magnesium, calcium, and creatinine concentrations. The exclusion criteria mitigated potential confounding factors. AUR cases exhibited significantly lower magnesium (5.97 vs.3.87, p = 0.031), calcium (11.04 vs. 5.3, p = 0.022), and creatinine (149.9 vs. 66.0, p = 0.005) levels (mg/dL) compared to controls. After adjusting for creatinine levels, no intergroup differences were observed. An inverse linear correlation was noted between the International Prostate Symptom Score and magnesium level (R2 = 0.15, p = 0.009). A magnesium cut-off of 3.57 mg/dL demonstrated 82.6 % sensitivity, 56.5 % specificity, and an AUC of 0.70. Patients with magnesium levels below 3.57 mg/dL had an 80 % higher risk of AUR (OR: 1.80, 95 % CI: 1.08-3.01, p = 0.016). This study highlights urinary magnesium as a potential marker for risk of AUR, paving the way for larger prospective studies in this intriguing domain. Future interventions that manipulate magnesium levels may offer innovative avenues for managing lower urinary tract disorders.</p>","PeriodicalId":18159,"journal":{"name":"Magnesium research","volume":"37 2","pages":"76-80"},"PeriodicalIF":1.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142729876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of dietary magnesium intake on cognitive decline related to olfactory impairment in older adults: a cross-sectional study from the NHANES database.","authors":"Dong Wang, Jinxiong Yang, Bo Liu, Wenlong Luo","doi":"10.1684/mrh.2024.0530","DOIUrl":"https://doi.org/10.1684/mrh.2024.0530","url":null,"abstract":"<p><p>Olfactory impairment in the elderly has been shown to be associated with an increased risk of cognitive decline, and oxidative stress may be involved in this process. Dietary magnesium (Mg), as an antioxidant dietary nutrient, has been reported to be associated with cognitive decline. This study aimed to explore the effect of dietary Mg intake on cognitive decline related to olfactory impairment in older adults. Data were extracted from the National Health and Nutrition Examination Survey (NHANES) database 2013-2014. Information on dietary Mg intake was obtained from 24-hour interview. Assessment of cognitive decline included four evaluation dimensions: the Consortium to Establish a Registry for Alzheimer's Disease (including immediate and delayed), an animal fluency test, and a digit symbol substitution test. Weighted univariable and multivariable linear regression models were utilized to explore the effect of Mg on cognitive decline related to olfactory impairment, using β values and 95% confidence intervals (CIs). Subgroup analyses based on gender, history of diabetes, cardiovascular disease (CVD) and depression were further assessed. In total, 1,388 elderly people were included, of whom 319 (22.98%) had olfactory impairment. After adjusting for all covariates, there was an inverse relationship between high Mg intake and cognitive decline (β=-0.21, 95%CI: -0.37 to -0.04), and olfactory impairment was positively associated with cognitive decline (β=0.53, 95%CI: 0.28 to 0.77). Among the elderly with olfactory impairment, the odds of cognitive decline were reduced in the high Mg intake group (β=0.37, 95% CI: 0.04 to 0.71) compared to the low Mg intake group (β=0.67, 95%CI: 0.39 to 0.96), especially among the elderly who were female (β=0.53, 95% CI: 0.09 to 0.98), with diabetes (β=0.72, 95% CI: 0.46 to 0.99), and without CVD (β=0.33, 95% CI: 0.05 to 0.61) and depression (β=0.38, 95% CI: 0.06 to 0.70). Adequate dietary Mg intake may provide potential beneficial effects, improving cognitive function, among elderly patients with olfactory impairment, which should be confirmed by scale-large prospective studies.</p>","PeriodicalId":18159,"journal":{"name":"Magnesium research","volume":"37 2","pages":"81-94"},"PeriodicalIF":1.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142729874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Magnesium chloride supplementation reduces risk of gestational diabetes by improving glucose levels and controlling body weight gain in diet-induced obese, hypomagnesaemic rats: a pilot study.","authors":"Claudia I Gamboa-Gómez, Pablo Alvarado-Aguilar, Gerardo Martínez-Aguilar, Jazel Barragán-Zuñiga, Martha Rodríguez-Morán, Fernando Guerrero-Romero","doi":"10.1684/mrh.2025.0545","DOIUrl":"https://doi.org/10.1684/mrh.2025.0545","url":null,"abstract":"<p><p>The role of magnesium supplementation in reducing the risk of gestational diabetes (GD) has not been elucidated. To evaluate the effect of magnesium chloride (MgCl2) on the risk of developing GD in a model of obese rats with hydrochlorothiazide-induced hypomagnesemia. Female Wistar rats were allocated into a healthy control or obese group. Obesity was induced with an obesogenic diet and defined by a body weight 30% higher than that of the healthy control group. Once obesity was induced and before pregnancy, hypomagnesemia was generated using hydrochlorothiazide (5 mg/kg body weight). Subsequently, the oestrous cycle was evaluated to proceed for mating. Once pregnancy was confirmed, the obese rats were allocated to an intervention group (IG) or control group (HOCG). Rats in the IG received MgCl2 (50 mg/kg body weight, equivalent to 500 mg per day in humans). Fasting glucose and ionized magnesium levels were determined on days 6, 15, and 20 of pregnancy. An oral glucose tolerance test was performed on day 15 of pregnancy. Rats in the IG had significantly increased ionized magnesium (p=0.009), decreased fasting (p=0.02) and two-hour post-load (p=0.04) glucose levels, and exhibited lower body weight gain than the HOCG (p<0.05). At the end of the study, 75% of the rats in the HOCG, but none in the IG, fulfilled the diagnostic criteria for GD. In obese hypomagnesaemic rats, magnesium supplementation, using MgCl2, reduces fasting and two-hour post-load glucose levels as well as the risk of developing GD, and induces lower body weight gain during pregnancy.</p>","PeriodicalId":18159,"journal":{"name":"Magnesium research","volume":"38 2","pages":"45-55"},"PeriodicalIF":1.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of intraoperative administration of magnesium on residual neuromuscular blockade: a retrospective cohort study.","authors":"Insun Park, Jiwon Yoon, Jiwon Han, Ah-Young Oh","doi":"10.1684/mrh.2025.0547","DOIUrl":"https://doi.org/10.1684/mrh.2025.0547","url":null,"abstract":"<p><p>Magnesium has been used as an adjuvant to general anaesthesia owing to its multiple benefits, including potentiating the action of rocuronium. However, magnesium may affect neostigmine-induced neuromuscular blockade recovery. The effects of intraoperative magnesium administration on residual neuromuscular blockade (RNMB) were investigated. This retrospective study reviewed the data of adult patients who underwent general anaesthesia with rocuronium as the neuromuscular blocking agent and neostigmine as the reversal agent, between 2018 and 2020. RNMB was defined as the administration of an additional reversal agent (neostigmine or sugammadex) in the post-anaesthesia care unit. The incidence of RNMB was compared between magnesium and control groups, and logistic regression analysis identified risk factors. Of 61,471 patients, 23,523 were included in the logistic regression analysis. After propensity score matching, 5166 patients from each group were compared, and RNMB incidence was comparable between the magnesium and control groups. In the logistic regression analysis, the risk factors for RNMB were older age (odds ratio: 1.02; 95% confidence interval: 1.01-1.03; p<0.001), male gender (1.72; 1.33-2.23; p<0.001), higher American Society of Anesthesiologists physical status (2.08; 1.54-2.82; p<0.001), limb surgery (1.46; 1.01-2.12; p=0.042), volatile anaesthetics, sevoflurane (1.84; 1.27-2.66; p=0.001), and intraoperative hypothermia (1.58; 1.13-2.23; p=0.008). Magnesium increased the risk of RNMB in patients anesthetized by propofol (2.22; 1.46-3.38; p<0.001) and sevoflurane (2.57; 1.60-4.11; p<0.001), but not desflurane (p≥0.05). Intraoperative magnesium increases the risk of RNMB in patients anesthetized with propofol and sevoflurane, and should be used with caution depending on the type of general anaesthetic agent administered.</p>","PeriodicalId":18159,"journal":{"name":"Magnesium research","volume":"38 2","pages":"70-80"},"PeriodicalIF":1.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between dietary magnesium intake and liver fibrosis among type 2 diabetes mellitus patients: a cross-sectional study from the NHANES database.","authors":"Yao Chen, E Weiqin, Jing Zhou, Zhengwen He","doi":"10.1684/mrh.2024.0527","DOIUrl":"https://doi.org/10.1684/mrh.2024.0527","url":null,"abstract":"<p><p>Liver fibrosis (LF) is a common complication of type 2 diabetes mellitus (T2DM). Studies have found that dietary magnesium (Mg), as an antioxidant nutrient, may be related to the occurrence and development of liver diseases. The aim of the present study was to evaluate the association between dietary Mg and the risk of LF in T2DM patients. In this cross-sectional study, data of T2DM patients, aged ≥18 years, were extracted from the National Health and Nutrition Examination Survey (NHANES 2017-2018). Dietary Mg intake information was obtained by 24-hour dietary recall review. Covariates included sociodemographic information, lifestyle, laboratory data, disease history and medication history, extracted from the database. Weighted univariable and multivariable logistic regression models were used to assess the association between dietary Mg intake and LF among T2DM patients, with odds ratio (OR) and 95% confidence interval (CI). Subgroup analyses based on patients with or without a history of hepatic steatosis were further assessed. A total of 945 participants were finally included, of whom 219 (23.17%) had LF. After adjusting for covariates, a high level of dietary Mg intake (OR=0.40, 95% CI: 0.17-0.93) was associated with lower odds of LF in T2DM patients, especially in patients with a history of hepatic steatosis (OR=0.39, 95% CI: 0.17-0.87). High dietary Mg intake has potential benefits in maintaining a healthy liver in T2DM patients. Sufficient Mg-rich foods and Mg supplementation may be beneficial for liver health management among T2DM patients. Further cohort studies are needed to confirm these findings.</p>","PeriodicalId":18159,"journal":{"name":"Magnesium research","volume":"37 1","pages":"33-44"},"PeriodicalIF":1.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141792867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}